Physicians' Academy for Cardiovascular Education
Member

LDL lowering for CVD prevention: From hypothesis to axiom

Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA
Prof. John Kastelein argues that after FOURIER and SPIRE 1&2, there can no longer be any doubt that lowering LDL is crucial for CVD prevention.

PCSK9 Expert Opinions Prof. John Kastelein explains the most important points from FOURIER and SPIRE 1&2. He argues that there can no longer be any doubt that lowering LDL is crucial for CVD prevention.

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA
Prof. John Chapman gives his personal views on the results of FOURIER and SPIRE 1&2 and the implications for LDL-c lowering in high-CV risk individuals.

PCSK9 Expert Opinions Prof. John Chapman gives his personal views on the results of FOURIER and SPIRE 1&2. Key question is whether in the light of the new data, the LDL-c goal will be maintained or lowered in high-CV risk individuals.

Initiation digoxin therapy associated with increased mortality in AF patients

Presented at ACC.17 by Renato D. Lopes

Mar. 23, 2017 - news

ACC 2017 AF patients starting digoxin treatment showed increased mortality, especially in the first 6 months, irrespective of the coexistence of HF, and digoxin concentrations >1.2 ng/ml should be avoided.

No convincing evidence of measurable verbal or nonverbal memory dysfunction due to statin

Gepresenteerd tijdens ACC.17 door Beth Taylor

Mar. 23, 2017 - news

ACC 2017 First study investigating the effects of statins on the CNS using fMRI, showed few differences between atorvastatin 80 mg and placebo in standardised neuropsychological tests.

Paroxysmal AF associated with worse clinical outcomes than persistent AF

Presented at ACC.17 by JJV McMurray

Mar. 23, 2017 - news

ACC 2017 Paroxysmal AF was associated with a higher risk of HF hospitalisation and stroke, while new-onset AF was associated with a higher risk of HF hospitalisation, death and stroke.

Angiotensin receptor-neprilysin inhibitor reduces HbA1c levels

Presented at ACC.17 by Jelena Seferovic

Mar. 21, 2017 - news

ACC 2017 In addition to its cardiovascular benefits, sacubitril/valsartan also reduces HbA1c levels, compared to enalapril.

High sensitive troponin T predicts 30-day mortality after non-cardiac surgery

Presented at ACC.17 by PJ Devereaux

Mar. 19, 2017 - news

ACC 2017 In non-cardiac surgery patients, a peak postoperative hsTnT measurement ≥ 20 ng/L and an absolute change of ≥ 5 ng/L was significantly associated with 30-day mortality.

Uninterrupted NOAC superior to warfarin for ablation of AF in the RE-CIRCUIT study

Presented at ACC.17 by Hough Calkins

Mar. 19, 2017 - news

ACC 2017 In AF patients undergoing ablation, periprocedural anticoagulation with uninterrupted dabigatran (150 mg twice daily) compared with warfarin was associated with fewer bleeding complications.

e-Counselling tool enhanced efficacy of usual care for hypertension

Presented at ACC.17 by Rob Nolan

Mar. 19, 2017 - news

ACC 2017 The REACH trial demonstrated that after 12 months of use of an e-counselling programme, hypertensives showed 10 mmHg lower SBP and improvement of other risk factors.

Revascularisation on non-infarct-related lesions during primary PCI in STEMI patients

Presented at ACC.17 by Pieter C Smits

Mar. 18, 2017 - news

ACC 2017 In STEMI patients with multi-vessel disease, fractional flow reserve-guided complete revascularisation of non–infarct-related lesions during primary PCI, reduced the risk of MACCE.

HDL-C mimetic did not induce plaque regression in post-ACS patients

Presented at ACC.17 by Stephen J Nicholls

Mar. 18, 2017 - news

ACC 2017 In post-ACS patients with at least one site with percent atheroma volume >30% in the proximal 10 mm of the target vessel, CER-001 did not lead to significant plaque regression in the CARAT study.

Safety of NOAC instead of aspirin in ACS patients

Presented at ACC.17 by Magnus E Ohman

Mar. 18, 2017 - news

ACC 2017 A safety study of rivaroxaban versus aspirin on top of P2Y12 therapy in ACS patients, showed that this dual antithrombotic regimen had a similar risk of clinically significant bleeding.